Filing Flows › West Pharmaceutical Services (WST) › Proprietary Products revenue
West Pharmaceutical Services (WST) Proprietary Products revenue by quarter
West Pharmaceutical Services' Proprietary Products revenue was $729M in Q3 2026 (third quarter 2026), +0.9% from Q2 2026. Over the last 7 quarters it ranged from $563M (Q1 2025) to $729M (Q3 2026).
| Quarter | Proprietary Products revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $729M | +0.9% | +13% |
| Q2 2026 | $723M | +4% | +17% |
| Q1 2026 | $694M | +5% | +23% |
| Q4 2025 | $662M | +2% | — |
| Q3 2025 | $648M | +4% | — |
| Q2 2025 | $620M | +10% | — |
| Q1 2025 | $563M | — | — |
Q3 2026 at a glance
West Pharmaceutical Services, Q3 2026: revenue $874M (+9% year over year), operating margin 30.6%, net earnings $214M, operating cash flow $190M. The chart follows the revenue to costs, profit and cash.
Questions
What is West Pharmaceutical Services' Proprietary Products revenue?
West Pharmaceutical Services' Proprietary Products revenue was $729M in Q3 2026 (third quarter 2026), +0.9% from Q2 2026.
How has West Pharmaceutical Services' Proprietary Products revenue changed?
Over the last 7 quarters it ranged from $563M (Q1 2025) to $729M (Q3 2026).
Q3 2026 results → · How West Pharmaceutical Services makes money →